We reviewed 86 cases of human immunodeficiency virus and tuberculosis coinfection; 34.9% were caused by Mycobacterium bovis. Patients with M. bovis infection were more likely to have advanced immunosuppression (CD4 T cell counts р200 cells/mL). Hispanic ethnicity, male sex, and abdominal disease were strongly associated with M. bovis disease.
We reviewed 86 cases of human immunodeficiency virus and tuberculosis coinfection; 34.9% were caused by Mycobacterium bovis. Patients with M. bovis infection were more likely to have advanced immunosuppression (CD4 T cell counts р200 cells/mL). Hispanic ethnicity, male sex, and abdominal disease were strongly associated with M. bovis disease.
Although Mycobacterium tuberculosis causes most cases of human tuberculosis (TB), Mycobacterium bovis is an important cause of TB infections in certain populations [1] [2] [3] [4] . A high prevalence of M. bovis disease in San Diego County has been reported among Hispanics of Mexican origin [3, 5, 6] . Human immunodeficiency virus (HIV) infection may be an important risk factor for M. bovis disease, and M. bovis has been associated with increased mortality [5] . Prior studies have not characterized how HIV-related factors, such as CD4 T cell counts and coexisting opportunistic infections, might influence mortality and the clinical presentation of M. bovis disease [3, 5, 7] . We performed a detailed retrospective analysis of TB among HIVinfected patients followed at the University of California, San Diego HIV (Owen) Clinic to further characterize M. bovis disease in HIV-infected adults.
Methods. We reviewed all culture-confirmed adult cases of HIV-TB coinfection due to M. tuberculosis and M. bovis at University of California, San Diego, from January 2000 through December 2007. Cases were identified through a comprehensive search of the Owen clinic database for all TB-related diagnoses and hospital discharge diagnoses using International Classification of Diseases, Ninth Revision, codes 10-018, and only culture-confirmed cases were included. Specimens were identified as either M. bovis or M. tuberculosis with use of standard biochemical tests (niacin strip test, nitrate reduction test) and susceptibility to pyrazinamide [8] .
Demographic and clinical data were collected through review of paper and electronic medical records. For patients with missing outcomes or mycobacterial culture information, additional follow-up data were obtained from the San Diego County Health Department TB program. The study protocol was approved by the Institutional Review Board of University of California, San Diego, and the San Diego County Department of Health and Human Services.
We conducted a retrospective case-control study examining sociodemographic and clinical characteristics associated with HIV infection and M. bovis versus M. tuberculosis disease. Demographic and clinical characteristics and mortality outcomes were compared using t tests for continuous data and Fisher's exact test for categorical data. For nonparametric data, the Wilcoxon rank-sum test was applied. No adjustments for multiple comparisons were made and a P value of .05 was considered to be statistically significant. A multivariable logistic regression model was used to evaluate the relationship between the TB species and sociodemographic and clinical characteristics. Covariates considered in the multivariable model were selected based on univariate test results, existing literature, and variable clustering [4, 5, 9] . These covariates included age, sex, Hispanic ethnicity, HIV risk factors, presence of AIDS-defining illness, CD4 T cell count, abdominal/extrapulmonary TB disease, and uninsured status. All analyses were conducted using SAS, version 9.2 (SAS Institute).
Results. From 2000 through 2007, a total of 110 cases of adult HIV-TB coinfection were identified in the Owen Clinic patient population; 86 patients had culture-confirmed TB due to M. tuberculosis or M. bovis. Twenty-three culture-negative patients were excluded; 1 patient with simultaneous M. bovis and M. tuberculosis infection was also excluded. Of the 86 TB cases included in the analysis, 30 (34.9%) were identified as M. bovis.
Sociodemographic and clinical characteristics were compared between M. bovis and M. tuberculosis cases ( Table 1 ). The majority of patients were Hispanic men with a median age of 39 years (range, 21-72 years). The median CD4 count and HIV RNA level were 64 cells/mm 3 (range, 4-456 cells/mm 3 ) and 200,885 copies/mL (range, !50 to 1750,000 copies/mL), re- ). All the P p .55 patients with multidrug-resistant TB were alive at the end of treatment.
Most patients had advanced immunosuppression (CD4 count р200 cells/mL); the median CD4 counts were not significantly different between the 2 groups. However, 10 (17.9%) of the M. tuberculosis case patients had a CD4 T cell count 1200 cells/mL, compared with 0 (0%) of the M. bovis case patients ( ). The majority of patients in both groups P p .01 were already known to have HIV infection, were not receiving antiretroviral therapy, and did not have concurrent or prior AIDS-defining illnesses at the time of TB diagnosis, and no statistical differences between the M. bovis and M. tuberculosis groups were found.
In the multivariable regression model, only male sex (odds ratio, 12.02; 95% confidence interval, 1.20-120.76), Hispanic ethnicity (odds ratio, 15.60; 95% confidence interval, 1.07-228.49), and abdominal disease (odds ratio, 42.29; 95% confidence interval, 6.92-258.35) remained significantly associated with M. bovis. Disease site (pulmonary, extrapulmonary, or both) and abdominal disease were highly clustered, and thus, only abdominal disease remained in the model.
No significant difference was found in mortality. There were 3 deaths (10.0%) among patients with M. bovis and 2 deaths (3.6%) among those with M. tuberculosis infection. Treatment outcome could not be determined for 1 M. bovis case patient (3.3%) and 2 M. tuberculosis case patients (3.6%) because the patients moved or were lost to follow-up.
Discussion. From 2000 through 2007, M. bovis was relatively common in our HIV-infected patient population, accounting for 34.9% of all TB cases. In contrast, M. bovis accounted for only 6.4% of all adult TB cases in San Diego County from 1994 through 2005 and 1.4% of reported cases nationwide [4, 5] . Cicero et al [11] report a 13.8% prevalence of M. bovis infection among HIV-TB coinfection cases in Mexico, whereas Rodwell et al [5] found that 25.0% of HIV-TB coinfection cases in San Diego County during 1995-2004 were caused by M. bovis. In addition, 14.3% of M. bovis case patients died during treatment, compared with 7.6% of M. tuberculosis case patients [5] . In our study, mortality was 10.0% for M. bovis case patients, compared with 3.6% for M. tuberculosis case patients, but this difference was not statistically significant. Our study had sought to explore factors that may have impacted the previously reported higher mortality associated with M. bovis disease [5] .
Although median CD4 T cell counts were not statistically different between the 2 groups, patients with M. bovis TB were more likely to have advanced immunosuppression, with no cases occurring in patients with CD4 T cell counts 1200 cells/ mL. In contrast, 17.8% of patients with M. tuberculosis TB had a CD4 T cell count 1200 cells/mL. Other HIV-related variables that could impact mortality, including antiretroviral treatment and presence of concurrent or prior aids-defining illness, were not significantly different between the groups. In addition, lack of health insurance, which could affect access to medical care, although more common in patients with M. bovis TB, was not significantly different between the groups. In our study, abdominal TB was strongly associated with M. bovis, occurring in 83.3% of patients. Lobue et al [3] found that abdominal disease was 9 times more frequent in M. bovis than in M. tuberculosis infection. The acquisition of M. bovis in the United States is hypothesized to be largely through the ingestion of unpasteurized, contaminated dairy products [4, 5, 10] . The possible gastrointestinal portal of entry and commonly observed clinical feature of abdominal disease are similar to HIV-associated disseminated Mycobacterium avium complex disease [11] . M. bovis has been found in dairy herds in some parts of Mexico and has been isolated from unpasteurized dairy products originating from Mexico but found in the United States [10, 12] . The risk associated with such consumption is not limited to border regions such as San Diego; 35 M. bovis cases in New York were attributed to the consumption of Mexican cheese [13] .
Our study was limited by the small sample size and the retrospective design, which restricts conclusions that can be drawn about mortality and predictive value of HIV-related factors. Although the overall number of TB cases and deaths was small, the comprehensive database maintained in our HIV program and our direct relationship with the San Diego County TB Control Branch allowed us to capture all reported cases of TB and all deaths occurring in our population. Our cohort is not inclusive of all HIV-infected patients in the San Diego County catchment area, although our clinic is a major provider of HIV care to uninsured and underinsured patients in San Diego County, and many are of Hispanic ethnicity. As such, we may have an overrepresentation of patients at risk for M. bovis TB. San Diego County TB data for M. bovis and HIV was only available for [2004] [2005] [2006] [2007] . During this time period, 25 (34.7%) of 72 M. tuberculosis-HIV coinfection cases were followed at the Owen Clinic, compared with 13 (52.0%) of 25 M. bovis-HIV coinfection cases. Finally, we excluded children in our study; characteristics of HIV-associated M. bovis disease may be different in children, compared with adults.
In conclusion, TB caused by M. bovis was common in our clinic population of HIV-infected patients and was strongly associated with both Hispanic ethnicity and disseminated disease with abdominal involvement. We agree with others that unpasteurized dairy products are a likely source of acquisition and that HIV care providers should be aware of this risk and counsel patients appropriately [4, 5] .
